İnan Gonca Altınışık, Aral Ipek Pinar, Arslan Aliye, Celik Tuğba Ozkader, Ozturk Huseyin Furkan, Arslan Suheyla Aytac, Tezcan Yilmaz
Radiation Oncology, Ankara Şehir Hastanesi, Radyasyon Onkolojisi Bölümü, Ankara Yildirim Beyazit Universitesi Tip Fakultesi, Ankara, Turkey.
Radiation Oncology, Ankara City Hospital, Cankaya, Turkey.
Rep Pract Oncol Radiother. 2022 Dec 29;27(6):973-981. doi: 10.5603/RPOR.a2022.0121. eCollection 2022.
This study aimed to evaluate acute toxicity and oncological outcomes of breast cancer patients who underwent adjuvant radiotherapy (RT) with tomotherapy.
The results of 114 patients who underwent adjuvant RT with Tomotherapy device between 17.08.10-12.06.2021 in Ankara Atatürk Training and Research Hospital and Ankara City Hospital were evaluated retrospectively. The primary endpoint of the study was acute adverse events, and the secondary endpoints were overall survival (OS) and disease-free survival (DFS).
The results of 103 patients who met the inclusion criteria were analyzed. The median follow-up was 21 (range 1-125.8) months. Grade +3 esophagitis was not observed in any patient; no esophagitis was observed in 60 (58.3%) patients. Grade 3 dermatitis was observed in 3 (2.9%) patients. In addition, dermatitis was not observed in 47 (45.6%) patients. The relationship between chest wall volume and esophagitis development was statistically significant (p = 0.006; Z score: -2769). The median OS was 24.1 (range 1-128.5) and median disease-free survival was 21.1 (range 1-125.8) months. Five patients (4.9%) died and 9 patients (8.7%) relapsed. Local recurrence was observed in only 1 (1%) patient. There was a statistically significant correlation between OS and contralateral lung V20 dose [p < 0.001; Spearman Correlation Coefficient (SCC) -406) and heart mean dose (p < 0.001; SCC -370)]. There was a statically significant correlation between DFS and cN (p < 0.001); pN (p < 0.001); heart mean dose (p < 0.001; SCC -351); contralateral lung V5 dose (p = 0.041; SCC -213); contralateral lung V20 dose (p < 0.001; SCC -434).
Acute toxicity results show improvement in breast cancer adjuvant radiotherapy with helical tomotherapy.
本研究旨在评估接受螺旋断层放射治疗（Tomotherapy）辅助放疗的乳腺癌患者的急性毒性和肿瘤学结局。
回顾性评估了2010年8月17日至2021年6月12日期间在安卡拉阿塔图尔克培训与研究医院及安卡拉市医院使用Tomotherapy设备接受辅助放疗的114例患者的结果。本研究的主要终点是急性不良事件，次要终点是总生存期（OS）和无病生存期（DFS）。
分析了符合纳入标准的103例患者的结果。中位随访时间为21（范围1 - 125.8）个月。所有患者均未观察到3级食管炎；60例（58.3%）患者未观察到食管炎。3例（2.9%）患者观察到3级皮炎。此外，47例（45.6%）患者未观察到皮炎。胸壁体积与食管炎发生之间的关系具有统计学意义（p = 0.006；Z值：-2769）。中位总生存期为24.1（范围1 - 128.5）个月，中位无病生存期为21.1（范围1 - 125.8）个月。5例（4.9%）患者死亡，9例（8.7%）患者复发。仅1例（1%）患者观察到局部复发。总生存期与对侧肺V20剂量[p < 0.001；Spearman相关系数（SCC）-406]和心脏平均剂量（p < 0.001；SCC -370）之间存在统计学显著相关性。无病生存期与cN（p < 0.001）；pN（p < 0.001）；心脏平均剂量（p < 0.001；SCC -351）；对侧肺V5剂量（p = 0.041；SCC -213）；对侧肺V20剂量（p < 0.001；SCC -434）之间存在统计学显著相关性。
急性毒性结果显示螺旋断层放疗在乳腺癌辅助放疗中有所改善。
